Featured Research

from universities, journals, and other organizations

Researchers Find Potential Celebrex Target In Lung Cancer

Date:
July 19, 2005
Source:
University of California - Los Angeles
Summary:
A product produced by lung cancer tumors fuels the cells that suppress immune function in patients and may be a target for Celebrex therapy, giving oncologists another weapon to fight cancer, according to a study by researchers at UCLA's Jonsson Cancer Center.

A product produced by lung cancer tumors fuels the cells that suppress immune function in patients and may be a target for Celebrex therapy, giving oncologists another weapon to fight cancer, according to a study by researchers at UCLA's Jonsson Cancer Center.

Researchers found that PGE2, which is produced normally by epithelial cells but at very high levels in lung cancer and other malignancies, up-regulates the activity of lymphocytes called T-regulatory cells, which suppress immune function, making it even harder for a patient to fight cancer. For the first time, UCLA researchers showed that PGE2 increases the growth and function of T-regulatory cells, making them more effective immune suppressors, said Dr. Steven Dubinett, director of the Lung Cancer Research Program at UCLA's Jonsson Cancer Center and senior author of the study.

The study appears in the July 15, 2005, issue of the peer-reviewed Journal of Immunology.

"We know that COX-2 inhibitors like Celebrex decrease PGE2, so when we discovered that PGE2 was fueling the T-regulatory cells, we knew we had a therapy we could test," said Dubinett, also a professor of pulmonary and critical care medicine and director of the Specialized Program of Research Excellence (SPORE) in lung cancer. "This discovery opens up the possibility that we could utilize relatively non-toxic drugs to augment immune responses in cancer patients."

The COX-2 inhibitors could be given with chemotherapy and immunotherapy drugs to help boost immune function in patients and help them to better fight cancer, Dubinett said.

Dubinett and his research team had hypothesized that PGE2 might be involved in suppression of the immune system. They first tested the theory in animal models and found that PGE2 was fueling the growth and function of the T-regulatory cells. Using Celebrex, researchers were able to decrease in number and function the T-regulatory cells by blocking PGE2. That study appeared in the June 15 issue of the peer-reviewed journal Cancer Research.

Dubinett and his team then validated their work in human cancer cell lines, the basis of the Journal of Immunology study. Again, administration of Celebrex decreased the number and function of T-regulatory cells, providing a boost to the immune system.

"Our data indicate that regulation of PGE2 production may in turn modulate T-regulatory cell development and function," the study states. "These findings suggest new therapeutic strategies targeting PGE2 in the prevention and treatment of cancer."

UCLA is launching a pilot study led by Dr. Karen Reckamp, an assistant professor of hematology/oncology, to further test their findings. Reckamp is seeking 24 patients with advanced lung cancer to participate in the study. Patients would take Celebrex for a week so researchers can study the drug's affect on the T-regulatory cells. Patients would give blood before taking Celebrex and after the week-long course of therapy, Reckamp said, giving researchers a clue as to whether the drug will function in humans the way it has in cell and animal models.

For more information on the study, call 310-825-5688.

Dubinett said the clinical research study being conducted by Reckamp will begin to provide important information by determining if this therapy can contribute to augmenting immune responses in patients with lung cancer.

"If this research holds true in patients, it could provide a new avenue for using this drug in combination with other therapies to fight lung cancer," he said.

UCLA's Jonsson Comprehensive Cancer Center is made up of more than 240 cancer researchers and clinicians engaged in cancer research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson Cancer Center is dedicated to promoting cancer research and translating the results into leading-edge clinical studies. In July 2005, the Jonsson Cancer Center was named the best cancer center in the western United States by U.S. News & World Report, a ranking it has held for six consecutive years.


Story Source:

The above story is based on materials provided by University of California - Los Angeles. Note: Materials may be edited for content and length.


Cite This Page:

University of California - Los Angeles. "Researchers Find Potential Celebrex Target In Lung Cancer." ScienceDaily. ScienceDaily, 19 July 2005. <www.sciencedaily.com/releases/2005/07/050719003438.htm>.
University of California - Los Angeles. (2005, July 19). Researchers Find Potential Celebrex Target In Lung Cancer. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2005/07/050719003438.htm
University of California - Los Angeles. "Researchers Find Potential Celebrex Target In Lung Cancer." ScienceDaily. www.sciencedaily.com/releases/2005/07/050719003438.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
CDC Calls for New Ebola Safety Guidelines

CDC Calls for New Ebola Safety Guidelines

AP (Oct. 20, 2014) Centers for Disease Control and Prevention Director Dr. Tom Frieden laid out new guidelines for health care workers when dealing with the deadly Ebola virus including new precautions when taking off personal protective equipment. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins